WASHINGTON, Oct. 15 (Xinhua) -- Anti-nausea drug metoclopramide taken during pregnancy was not associated with significantly increased risk of major congenital malformations, spontaneous abortion, and stillbirth, a study said Tuesday.
More than 50 percent of pregnant women experience nausea and vomiting, typically early in their pregnancy. The care of most women is managed conservatively, but 10 percent to 15 percent of those with nausea and vomiting will eventually receive drug treatment.
Metoclopramide is often recommended if treatment with an antihistamine or vitamin B6 has failed. Despite metoclopramide being one of the most commonly used prescription medications in pregnancy, data on the safety of its use in pregnancy are limited, researchers at Statens Serum Institut, Copenhagen, said.
They analyzed over 1.2 million pregnancies in Denmark from 1997 through 2011 to investigate associations between metoclopramide use and serious adverse outcomes. In this study, there were 28,486 live-born infants exposed to metoclopramide in the first three months of pregnancy and 113,698 unexposed infants.
Of these infants, 721 exposed, or 25.3 per 1,000 births, and 3, 024 unexposed infants, or 26.6 per 1,000 births, were diagnosed with any major malformation during the first year of life.
In analyses of individual malformation categories, the researchers found no associations between metoclopramide use in the first three months and any of the 20 malformations, including neural tube defects, cleft lip, cleft palate and limb reduction.
The researchers also observed no increased risk of spontaneous abortion, stillbirth, preterm birth, low birth weight, and fetal growth restriction associated with metoclopramide use in pregnancy.
"These safety data may help inform decision making when treatment with metoclopramide is considered in pregnancy," they concluded.
The findings were published in the Journal of the American Medical Association.
